From molecular case studies: Genomics of exceptional responder to NOTCH inhibitor

Normal T-cell development requires Notch signaling but hyperactivity can lead to cancer. Drugs that inhibit Notch, such as gamma-secretase inhibitors, are currently being tested in different cancer types but clinical remission has yet to be reported. In a new paper, researchers describe an acute lymphoblastic leukemia patient in which GSI treatment resulted in complete remission, suggesting that GSIs may hold therapeutic promise in ALL and other cancers. (Mehr in: Cancer News — ScienceDaily)